AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Additional effects included feeling stoned, alcohol-like intoxication, drifting of thoughts, and difficulty concentrating and cognitive impairment. The effects of the drug were described as highly dependent on set and setting, with prominent negative reactions in unfavorable environments or with too high of doses, including unpleasantness, anxiety, paranoia, social withdrawal, and unwillingness to take the drug again, among others. Physical effects of DET included DMT-like vegetative or autonomic symptoms, pupil dilation, sweating, slight burning and numbness of hands and feet, dizziness, vertigo, feeling sick, paleness, shakiness, muscle tremors, athetoid movements, vomiting, feeling of hollowness in the chest, pronounced tachycardia, pressor effects, and other somatic symptoms. Subsequent-day effects included an afterglow, hangover, lassitude, and cognitive fuzziness.
I am left with the impression that the attorneys in charge of the Labscam investigation ... seek to take far more credit for the overall success of the proceedings than is rightly due. Philadelphia-based SmithKline agreed to pay the government $325 million which is considered as one of the largest civil settlement ever in a whistle-blower lawsuit. The company settled after the government alleged it paid kickbacks to doctors, billed the government for laboratory tests not performed and committed other violations. SmithKline has denied the allegations, saying the violations were unintentional and the result of ambiguities in regulations and guidelines. When interest and payments to state Medicare funds were taken into account, the final settlement came to about $321 million. VanArtsdalen said Merena and the other whistle-blowers accounted for all but about $15 million of that total. The government failed to reach an agreement with litigants Merena and Grossenbacher on the amount that they would receive from the settlement agreement. The government maintained that Merena was entitled to approximately $10 million of the $65 million attributable to the non-"automated chemistry" claims and has paid Merena this amount. The government and the Spear relators have a proposed agreement that, if approved, will award the Spear relators 15% of the $13 million that the government attributed to a claim called the "CBC Indices" claim. The government previously agreed to pay the whistle-blowers a minimum of $9.7 million but only if they dropped claims to a larger portion.
The single filament method is also possible. Once the sample evaporates, the analytes can settle back down onto the same filament to get ionized. The use of a triple filament or multifilament set-up improves ionization efficiency and provides the rate of evaporation and ionization to be controlled separately. Filaments need to be loaded with activators. An activator represses the evaporation of the desired element and can either increase or decrease the ionization potential of the filament. This results in high ionization efficiency and a higher total yield. The most common activator is silica gel/phosphoric acid for Pb. The filaments are in a vacuum that can reach temperatures anywhere from 400-2300°C. In order to prevent any damage to the filaments, they are firmly fixed onto a carousel-like sample turret which normally has 10 to 20 filament assemblies. The evaporation process is usually conducted at relatively low temperatures in exchange for long-lasting signals and minor isotopic fractionation. The ionization part requires high temperatures to ensure good ionization efficiency. The ions emitted have low spatial and energetic spread which makes a single-focusing magnetic sector mass analyzer or quadrupoles suitable. The most common detectors used for TIMS is Faraday cup, Daly detector, and electron multiplier. Customarily, TI ion sources are assembled with multicollector (MC) systems.
Sources: en.wikipedia.org
Australia and New Zealand: Similar to the agreement between India and Nepal, the Trans-Tasman Travel Arrangement between Australia and New Zealand is a free movement agreement citizens of each country to travel freely between them and allowing citizens and some permanent residents to reside, visit, work, study in the other country for an indefinite period, with some restrictions. The arrangement came into effect in 1973, and allows citizens of each country to reside and work in the other country, with some restrictions. Other details of the arrangement have varied over time. From 1 July 1981, all people entering Australia (including New Zealand citizens) have been required to carry a passport. Since 1 September 1994, Australia has had a universal visa requirement, and to specifically cater for the continued free movement of New Zealanders to Australia, the Special Category Visa was introduced for New Zealanders. Central America : The Central America-4 Border Control Agreement abolishes border controls for land travel between El Salvador, Honduras, Nicaragua, and Guatemala. However, this does not apply to air travel. Europe and the Middle East Union State of Russia and Belarus The Union State of Russia and Belarus is a supranational union of Russia and Belarus, which eliminates all border controls between the two nations. Before a visa agreement was signed in 2020, each country maintained its own visa policies, resulting in non-citizens of both countries generally being barred from travelling directly between them.
== Medical significance == Pathogenic (heterozygous) variants in YARS1 have been associated with peripheral nervous system dysfunction called type C dominant intermediate Charcot-Marie-Tooth neuropathy (CMTDIC).
=== Activation of emitters === The growth process of microneedles on emitters is termed ‘activation’. The tips of microneedles can provide high field strength for field desorption, and higher emission current can be obtained due to the increased emission area compared to metal tips. Some activation methods include high-temperature (HT) activation, high-rate (HR) activation, and electrochemical desorption. In the HT activation mode, a 10 μm tungsten wire is activated outside the mass spectrometer in a vacuum cell containing benzonitrile at a pressure of about 10−1 Pa. The tungsten wire serving as the field anode is then heated up to about 1500 K with direct current at a potential of about 10 kV with respect to a cathode. Carbon microneedles can be produced within 8-12 h. HR activation method is to reverse the polarity of the emitter and the counter electrode, which emits a strong electron current. The strong electron current results in the heating of the growing carbon needles and therefore the high rates of the needle growth. In the HR activation mode, needles of other metals (iron, nickel or cobalt) and of alloys can also be generated. Instead of carbon microneedles, metallic dendrites (mainly of nickel or cobalt) can be produced on thin wires through electrochemical desorption process. This method is even faster than HR method.
=== Awards === Half-Life: Alyx won "Game of the Year" at the 2020 VR Awards. At the Game Awards 2020, it was nominated for "Best Game Direction", "Best Audio Design" and "Best Action", and won for "Best VR/AR". At the 17th British Academy Games Awards, it was nominated for "Best Game", "Game Direction", "Audio Achievement" and "Artistic Achievement". At the 24th Annual D.I.C.E. Awards, it was nominated for "Action Game of the Year", "Outstanding Achievement in Game Direction", and "Outstanding Achievement in Game Design", and won for "Immersive Reality Technical Achievement" and "Immersive Reality Game of the Year".
Sources: en.wikipedia.org
=== Chemical industry === Many chemicals exhibit a specific rotation as a unique property (an intensive property like refractive index or specific gravity) which can be used to distinguish it. Polarimeters can identify unknown samples based on this if other variables such as concentration and length of sample cell length are controlled or at least known. This is used in the chemical industry. By the same token, if the specific rotation of a sample is already known, then the concentration and/or purity of a solution containing it can be calculated. Most automatic polarimeters make this calculation automatically, given input on variables from the user.
== Limits == Each individual is born with a particular range of motion for each joint in their body. In the 1964 book Finding Balance by Gigi Berardi, the author mentions three limiting factors: occupational demands, movement demands, and training oversights.
=== Articulata hypothesis === The grouping proposed by Aguinaldo et al. is almost universally accepted, replacing an older hypothesis that Panarthropoda should be classified with Annelida in a group called the Articulata, and that Ecdysozoa are polyphyletic. Nielsen has suggested that a possible solution is to regard Ecdysozoa as a sister-group of Annelida, though later considered them unrelated. Inclusion of the roundworms within the Ecdysozoa was initially contested but since 2003, a broad consensus has formed supporting the Ecdysozoa and in 2011 the Darwin–Wallace Medal was awarded to James Lake for the discovery of the New Animal Phylogeny consisting of the Ecdysozoa, the Lophotrochozoa, and the Deuterostomia.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.